Genmab stock gains as HC Wainwright lifts earnings estimates and confirms Buy rating

Published on 09/16/2026 at 16:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Genmab stock is supported on September 16, 2026 by HC Wainwright raising its Q3 2026 EPS estimate to USD 0.49 and reaffirming a USD 40.00 Buy target. The shares most recently opened around USD 34.15 on Nasdaq, below the consensus price target of USD 39.50.

Fotorealistisches Biotech-Labor mit Forschern in weißen Kitteln bei Antikörperforschung — Genmab A/S entwickelt Antikörpertherapien in modernen Biotech-Laboren mit Forschern und Präzisionsgeräten, Aktie DK0010272202, Illustration mit AI erstellt.

Genmab stock (ISIN DK0010272202) is trading supported on September 16, 2026 after HC Wainwright raised its earnings estimates and reaffirmed a Buy rating with a USD 40.00 price target on the Nasdaq-listed American Depositary Shares.

Analyst raises EPS estimates and confirms Buy rating

According to MarketBeat on September 16, 2026, HC Wainwright analyst R. Selvaraju increased his forecast for Genmab A/S's Q3 2026 earnings per share to USD 0.49, up from a previous estimate of USD 0.37.

This revision represents a quantified upgrade of roughly 32.4 percent in the Q3 2026 EPS expectation, underlining growing confidence in Genmab's operating momentum for the second half of 2026 as seen by HC Wainwright.

HC Wainwright simultaneously reiterated its Buy rating on Genmab stock and kept its USD 40.00 price target unchanged, positioning the shares with implied upside potential relative to the latest observed trading levels on Nasdaq.

The same MarketBeat overview reports that the consensus estimate for Genmab A/S's current full-year 2026 earnings stands at USD 1.17 per share, providing a baseline for investors to compare HC Wainwright's more optimistic quarterly and full-year projections.

Consensus view and extended earnings projections

As MarketBeat further notes, Genmab A/S currently carries a consensus rating of Moderate Buy among covering analysts, with a consensus price target of USD 39.50 for the Nasdaq-listed shares.

Relative to the USD 40.00 target maintained by HC Wainwright, the consensus target of USD 39.50 suggests that the broader analyst community is only marginally less optimistic than HC Wainwright on Genmab's valuation, reinforcing a generally constructive stance on the stock.

HC Wainwright also issued updated estimates for subsequent periods, expecting Q4 2026 earnings per share of USD 0.44 and full-year 2026 earnings of USD 1.48 per share, which stand above the USD 1.17 consensus figure cited in the same MarketBeat report.

These projections, focused on the 2026 reporting year, indicate that HC Wainwright sees earnings growth continuing into late 2026, which, if realized, could support the current Buy rating and the USD 40.00 price target for Genmab stock.

Stock performance and valuation context

Shares of Genmab A/S's Nasdaq-listed American Depositary Shares (ticker GMAB) opened at USD 34.15 on the most recent trading day referenced by MarketBeat, providing a concrete level for investors to compare against analyst targets.

At this USD 34.15 opening price, Genmab stock trades around USD 5.85 below HC Wainwright's USD 40.00 price target, implying potential upside of approximately 17.1 percent if the target is reached.

Measured against the consensus price target of USD 39.50, the same USD 34.15 share price suggests a discount of USD 5.35, corresponding to around 15.7 percent potential upside to the broader analyst community's average target.

In Genmab's home market, Genmab A/S (Nasdaq Copenhagen: GMAB) closed at DKK 2,150.00 on Nasdaq Copenhagen on September 15, 2026, marking a 1.61 percent gain for that session as reported by Ad-hoc-news.

According to session data cited in the same report, Genmab was described as the best performer within the OMX Copenhagen 20 index basket on September 15, 2026, with its 1.61 percent rise contrasting with a 0.84 percent decline in the broader Danish benchmark.

Market commentary referenced by that Copenhagen trading summary noted that Genmab's shares have shown positive six-month performance and were trading at a valuation multiple in the mid-20s on a price-earnings basis, framing the recent advance within a wider recovery pattern for the stock.

Investor takeaways from current estimates and price levels

The combination of HC Wainwright's upgraded Q3 2026 EPS estimate from USD 0.37 to USD 0.49, its maintained Buy rating and USD 40.00 price target, and a Moderate Buy consensus rating with a USD 39.50 average target gives investors a numerically rich picture of how the analyst community currently views Genmab stock.

With the Nasdaq-listed shares trading around USD 34.15 in the latest referenced data, the stock stands below both HC Wainwright's and the consensus price targets, suggesting that the market has yet to fully price in the higher near-term earnings expectations expressed in the September 16, 2026 MarketBeat alert.

In Copenhagen, the DKK 2,150.00 close and 1.61 percent gain on September 15, 2026, coupled with outperformance against the OMX Copenhagen 20 index, underline that Genmab stock has recently attracted buying interest in its home market, which can be an additional confidence signal for international investors watching both venues.

For shareholders, the quantified gap between current prices and the USD 39.50 to USD 40.00 range of price targets, alongside upgraded 2026 EPS projections, makes the coming quarterly results and guidance updates critical checkpoints in confirming whether the earnings trajectory can support the analyst valuations.

Stock price and market data

On Nasdaq, the Genmab A/S American Depositary Shares (ticker GMAB) most recently opened at USD 34.15 on the trading day highlighted by MarketBeat, with that level serving as the current reference price for this article as of mid-September 2026.